Organon earnings on deck as Sun Pharma merger awaits approval

Organon & Co. is set to release its third-quarter earnings on Monday as it waits for regulatory approval of a $14-per-share acquisition by Sun Pharmaceutical Industries. Analysts forecast earnings per share of $0.94 on revenue of $1.57 billion, indicating a slight revenue decline from the previous quarter's $1.60 billion and a 7.26% increase in EPS over the past 60 days.

The merger, announced in April and approved by stockholders in July, still requires regulatory approval. Organon's stock closed at $13.87, near the deal price, indicating investor confidence. However, analysts maintain a neutral rating with a mean price target of $10.33, implying a 25% downside. The company faces year-over-year declines in earnings and revenue due to the divestiture of its Jada product and ongoing challenges in legacy pharmaceutical products.

Three out of four analysts rate the stock as a hold, with one recommending a sell. The primary uncertainty is whether Organon will provide updates on the merger timeline or regulatory process. With the Jada divestiture behind it and mature products facing competitive pressures, investors need assurance that the business can stabilize its top-line decline.

Organon carries $8.64 billion in debt and has experienced negative EBITDA growth over the past year, making operational health critical if the merger encounters delays. Organon missed EPS expectations by 5.6% in August while exceeding revenue forecasts by 1.9%, highlighting execution challenges. Monday's results will provide insight into Organon's performance during a strategic period of uncertainty, with stock price suggesting deal certainty but underlying business metrics becoming crucial if regulatory approvals take longer or complications arise in the merger process.